权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical Validation of ER/PR Test Controls & Calibrators

ER/PR 测试对照的临床验证

基本信息

批准号：
7195793
负责人：
Steven A Bogen
金额：
$ 57.85万
依托单位：
BOSTON CELL STANDARDS INC
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-03-06 至 2009-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7195793
关键词：
Address Affect Amino Acids Antibody Binding Sites Antigens Bacteriophages Binding Biological Assay Biopsy Calibration Cancer Patient Caring Clinical Clinical Trials Condition Consensus Sequence Data Decision Making Diagnostic Diagnostic Procedure Diagnostic tests Disease Dissection Error Sources Estrogen Receptors Evaluation Fc Receptor Formalin Grant Guidelines Image Laboratories Lead Letters Link Malignant Neoplasms Materials Testing Measures Mechanics Methods Microscope Molecular Numbers Ontology Optics Pathologic Pathology Patients Peptide Receptor Peptides Performance Personal Satisfaction Phage Display Phase Phase II Clinical Trials Positioning Attribute Procedures Progesterone Receptors Property Purpose Quality Control Range Relative (related person)Reproducibility Research Retrieval Role Series Slide Source Specimen Staining method Stains Standardization Standards of Weights and Measures Surgical Pathology Tamoxifen Techniques Technology Test Result Testing Therapeutic Time Tissues United States Food and Drug Administration Validation base cancer care cancer diagnosis clinical Diagnosis clinically significant cost density design improved instrument malignant breast neoplasm novel diagnostics prevent programs prototype receptor response sample fixation steroid hormone receptor synthetic peptide tool

项目摘要

DESCRIPTION (provided by applicant) Phase I The long-term objective of this project is to improve the consistency and standardization of clinical cancer diagnostic testing of tissue biopsies. There are increasing numbers of cancer therapeutics that are linked to immunohistochemical diagnostic tests. Patient therapy is directly affected by the quantitative results of such testing. The absence of quantitative controls and calibrators seriously hampers the ability of laboratories to achieve consistent and standardized test results. Laboratories currently use pathologic discard tissue biopsies as controls, an inherently unstandardized source. In order to address this need, we developed the Analyte Controls technology. It provides an inexpensive, reproducible, and quantitative test material for detecting errors in staining procedure. This program aims to validate the clinical utility of this technology. In addition, this Phase I/Il Fast Track program is expected to lead to an FDA submission. For Phase I, we will address three technical aspects of the technology before launching into clinical trials. The Specific Aims of the Phase I grant are: (1) to create Analyte Controls for three new ER & PR antibodies. With these three, our Analyte Controls Slide will test for all of the commonly used ER and PR antibody clones, which is important prior to initiating clinical trials. (2) Identify Analyte Control peptides for ER and PR testing that distinguish pre-analytic sources of error (i.e., antigen retrieval) from analytic types of error, and (3) to demonstrate feasibility of a clinical laboratory slide densitometer that laboratories can use to quantify optical density of Analyte Controls on microscope slides. A method for precise quantification is required for clinical trials. The Analyte Controls for ER & PR will be the first quantitative control and calibrator for quantitative immunohistochemical testing that can be manufactured in inexhaustible amounts, relatively inexpensively, and in a reproducible fashion.

描述（由申请人提供）一期该项目的长期目标是提高组织活检临床癌症诊断测试的一致性和标准化。越来越多的癌症治疗方法与免疫组织化学诊断测试有关。患者治疗直接受到这种测试的定量结果的影响。缺乏定量控制和校准品严重妨碍了实验室获得一致和标准化测试结果的能力。实验室目前使用病理丢弃的组织活检作为对照，这是一种本质上不标准化的来源。为了满足这一需求，我们开发了分析物控制技术。它提供了一种廉价、可重复和定量的测试材料，用于检测染色过程中的错误。该计划旨在验证该技术的临床实用性。此外，该I/II期快速通道项目预计将导致FDA提交。对于第一阶段，我们将在进入临床试验之前解决该技术的三个技术方面。第一阶段资助的具体目标是：（1）为三种新的ER和PR抗体创建分析物对照。有了这三个，我们的分析物质控品载玻片将测试所有常用的ER和PR抗体克隆，这在启动临床试验之前很重要。(2)识别用于ER和PR检测的分析物对照肽，以区分分析前的误差来源（即，抗原修复）的分析类型的错误，以及（3）证明临床实验室载玻片密度计的可行性，实验室可以使用该密度计来量化显微镜载玻片上分析物对照的光密度。临床试验需要精确定量的方法。 ER和PR的分析物质控品将是第一个用于定量免疫组织化学检测的定量质控品和校准品，可以以取之不尽、相对便宜和可重复的方式生产。